Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in womenâ€™s sexual and reproductive health. The Companyâ€™s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
24/07/26	US$0.008200	-2.38%	77,083
23/07/26	US$0.008400	+8.39%	89,764
22/07/26	US$0.007750	-3.13%	123,319
21/07/26	US$0.008000	-0.74%	167,779
20/07/26	US$0.008060	+4.68%	26,537

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 19:21:22 24/07/2026 BST			5-day change	1st Jan Change
0.008200 ^USD	-2.38%		+6.49%	-13.68%

07-01	HUB Cyber Security Acquires Evofem Notes, Cuts Staff	MT
05-15	Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	1.09M 954K 888K 815K 1.53M 105M 1.55M 10.54M 4.12M 51.45M 4.08M 3.99M 178M	P/E 2024	-0.08x	P/E 2025	26.7x
Enterprise Value	55.5M 48.75M 45.34M 41.6M 78.17M 5.35B 79.37M 538M 210M 2.63B 208M 204M 9.09B	EV / Sales 2024	2.43x	EV / Sales 2025	2.76x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

07-01	HUB Cyber Security Acquires Evofem Notes, Cuts Staff	MT
05-15	Evofem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-27	Evofem Biosciences, Inc. and Clovis Davis Pharmaceuticals, LLC Enter Exclusive Distribution Agreement For SOLOSEC In Sub-Saharan Africa	CI
03-19	Evofem Biosciences, Inc. Announces Termination of License and Supply Agreement with No Fees Payable with Windtree Therapeutics, Inc	CI
03-11	Evofem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-10	Evofem Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-13	Evofem Biosciences Q3 net sales rise	RE
11-13	Evofem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
19/10/25	Aditxt, Inc. cancelled the acquisition of Evofem Biosciences, Inc. from Keystone Capital Partners LLC and others.	CI
01/10/25	Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates	CI
09/09/25	Evofem anticipates approval of merger with Aditxt at upcoming Stockholder Meeting	RE
14/08/25	Evofem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25/06/25	Evofem Biosciences, Inc. announced that it has received $0.925 million in funding from Aditxt, Inc.	CI

13/12/23	Laidlaw Downgrades Evofem Biosciences to Hold From Buy	MT
13/10/22	Stifel Downgrades Evofem Biosciences to Hold From Buy, Adjusts Price Target to $0.50 From $3	MT
15/08/22	HC Wainwright Adjusts Price Target on Evofem Biosciences to $4 From $2, Reiterates Buy Rating	MT
14/07/22	Morgan Stanley Adjusts Price Target for Evofem Biosciences to $0.75 From $2, Maintains Underweight Rating	MT
02/06/22	Laidlaw & Co. Initiates Evofem Biosciences at Buy with $3.50 Price Target	MT

Evofem Biosciences, Inc. Share Price

Stocks

EVFM

US30048L3024

Pharmaceuticals

Valuation: Evofem Biosciences, Inc.

Chart: Evofem Biosciences, Inc.

Latest news : Evofem Biosciences, Inc.

Analysts' recommendations: Evofem Biosciences, Inc.

Press Releases: Evofem Biosciences, Inc.

News in other languages: Evofem Biosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Evofem Biosciences, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

07-23	Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex	BU
05-18	Evofem Reports First Quarter 2026 Financial Results and Provides Business Update	BU
04-27	Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa	BU
03-11	Evofem Reports Fifth Consecutive Year of Net Sales Growth	BU
11-21	Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE	PR

25/03/21	KB Home : UPDATE/MÄRKTE USA/Anleger fassen im späten Geschäft Mut
25/03/21	KB Home : MÄRKTE USA/Anleger fassen im späten Geschäft Mut
25/03/21	KB Home : MÄRKTE USA/Verluste in volatilem Geschäft
25/03/21	KB Home : MÄRKTE USA/Wall Street startet leichter mit Sorgen um Geldpolitik
25/03/21	KB Home : MÄRKTE USA/Wall Street dürfte leichter starten

1 day	-2.38%
1 week	+6.49%
Current month	+2.50%
1 month	-5.75%
3 months	-5.75%
6 months	-9.89%
Current year	-13.68%

1 week	0.01	0.01
1 month	0.01	0.01
Current year	0	0.01
1 year	0	0.02
3 years	0	0.59
5 years	0	1,826.62
10 years	0	23,549.99

Manager	Title	Age	Since
Saundra Pelletier CEO	Chief Executive Officer	57	31/12/2017
Ivy Zhang DFI	Director of Finance/CFO	49	12/04/2023
Kathy Gallo-Doyle COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Saundra Pelletier CHM	Chairman	57	-
Kim Kamdar BRD	Director/Board Member	58	31/12/2017
Colin Rutherford BRD	Director/Board Member	67	31/12/2017

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/01/24	Ivy Zhang	Sell	Chief Financial Officer	104	0.0010%
21/12/23	Kim Kamdar	Sell	Director	10	0.0001%
13/04/23	Ivy Zhang	Other	Chief Financial Officer	13,000	0.0107%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOFEM BIOSCIENCES, INC.	-2.38%	+6.49%	-15.46%	-98.72%	1.09M
ELI LILLY AND COMPANY	+0.86%	+1.43%	+48.50%	+160.39%	1,067B
JOHNSON & JOHNSON	+1.59%	+4.09%	+55.34%	+53.96%	635B
ABBVIE INC.	+0.95%	+1.91%	+35.91%	+81.14%	458B
ROCHE HOLDING AG	+1.60%	+6.25%	+33.95%	+29.84%	347B
NOVARTIS AG	-0.60%	+1.52%	+35.68%	+39.76%	295B
ASTRAZENECA PLC	-0.14%	+0.60%	+16.17%	+17.53%	262B
NOVO NORDISK A/S	+0.09%	-2.82%	-28.29%	-41.71%	216B
AMGEN INC.	+1.22%	+2.66%	+21.87%	+59.73%	203B
GILEAD SCIENCES, INC.	-1.18%	-3.70%	+14.23%	+66.51%	161B
Average	+0.09%	+1.84%	+21.79%	+36.84%	364.3B
Weighted average by Cap.	+0.55%	+1.95%	+35.81%	+77.68%

	2024	2025
Net sales	19.36M 17.01M 15.82M 14.51M 27.27M 1.86B 27.69M 188M 73.37M 917M 72.69M 71.12M 3.17B	20.18M 17.73M 16.49M 15.13M 28.42M 1.94B 28.86M 196M 76.48M 956M 75.77M 74.13M 3.3B
Net income	-8.86M -7.78M -7.24M -6.64M -12.48M -853M -12.67M -85.94M -33.57M -419M -33.26M -32.54M -1.45B	391K 343K 319K 293K 551K 37.65M 559K 3.79M 1.48M 18.51M 1.47M 1.44M 64.01M
Net Debt	45.84M 40.26M 37.44M 34.36M 64.56M 4.41B 65.55M 445M 174M 2.17B 172M 168M 7.5B	54.42M 47.79M 44.45M 40.79M 76.63M 5.24B 77.82M 528M 206M 2.58B 204M 200M 8.91B